NAMS logo

NAMS

Profile

Full Name

NewAmsterdam Pharma Company N.V.

Ticker Symbol

NAMS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Netherlands

IPO

February 9, 2021

Indexes

Not included

Website

http://www.newamsterdampharma.com

Employees

68

Key Details

Price

$16.34(+1.93%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$45.56M(+223.37% YoY)

Annual EPS

-$2.56(-19.07% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$16.34
NAMS price is $16.34

30-Day Relative Volume

0.22
NAMS 30-day relative volume is 0.22

Price Performance

Price Today change

+1.93%
NAMS price is up +1.93% today

Price YTD change

-36.42%
NAMS price is down -36.42% since January 1st

Price 1-year change

-18.5%
NAMS price is down -18.5% year-on-year

Price 3-year change

+65.89%
NAMS price is up +65.89% over the past 3 years

Price Range

Price All-time high

$32.88
NAMS price is currently -50.30% below its historical high of $32.88

Price 3-year low

$5.63
NAMS price is currently +190.08% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$1.79B
NAMS market capitalization is $1.79 billion

Market cap 3-year change

-
NAMS market capitalization 3-year change is unknown

Market cap All-time high

$2.84B
NAMS market capitalization is currently -36.89% below its historical high of $2.84 billion

Market cap sector rank

82.4%
NAMS market capitalization is higher than 82.4% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+22.4%
NAMS shares outstanding is up +22.4% year-on-year

Shares Outstanding 3-Year Change

-
NAMS shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.79
NAMS beta is 0.79

200-day SMA

$19.98
NAMS price is currently -18.22% below its 200-day simple moving average

50-day SMA

$20.22
NAMS price is currently -19.17% below its 50-day simple moving average

RSI

33.41
NAMS 14-day relative strength index is 33.41

Volume

0.22
NAMS 30-day relative volume is 0.22

ATR

$1.50
NAMS average true range is $1.50

10-day Historical Volatility

90.96%
NAMS 10-day historical volatility is 90.96%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$45.56M
NAMS annual revenue is $45.56 million

Revenue Analysts estimate

$15.92M
NAMS annual revenue is currently +186.29% higher than the consensus analysts' forecast

Revenue 1-year change

+223.37%
NAMS annual revenue is up +223.37% year-on-year

Revenue Sector rank

45.58%
NAMS annual revenue is higher than 45.58% of companies in Healthcare sector

EPS

EPS

-$2.56
NAMS annual earnings per share is -$2.56

EPS Analysts estimate

-$1.73
NAMS annual earnings per share is currently +48.14% higher than the consensus analysts' forecast

EPS 1-year change

-19.07%
NAMS annual earnings per share is down -19.07% year-on-year

EPS Sector rank

33.8%
NAMS annual earnings per share is higher than 33.8% of companies in Healthcare sector

Profit

Gross profit

-
NAMS annual gross profit value is unknown

Gross margin

-
NAMS annual gross profit margin value is unknown

Operating profit

-$176.29M
NAMS annual operating income is -$176.29 million

Operating margin

-386.91%
NAMS annual operating profit margin is -386.91%

Net income

-$241.60M
NAMS annual net profit is -$241.60 million

Net margin

-530.25%
NAMS annual net profit margin is -530.25%

Expenses

Total expenses

$221.85M
NAMS annual total expenses is $221.85 million

Operating expenses

$221.85M
NAMS annual total operating expenses is $221.85 million

Cost of goods sold

-
NAMS annual cost of goods sold value is unknown

Selling, general & administrative expenses

$70.45M
NAMS annual SGA is $70.45 million

Depreciation and amortization

$113.00K
NAMS annual depreciation & amortization is $113.00 thousand

Interest expense

$0.00
NAMS annual interest expense is $0.00

Income tax

-$1000.00
NAMS annual income tax is -$1000.00

EBIT & EBITDA

EBIT

-$241.60M
NAMS annual earnings before interest & taxes is -$241.60 million

EBITDA

-$241.49M
NAMS annual EBITDA is -$241.49 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$864.62M
NAMS annual total assets is $864.62 million

Non current assets

$1.21M
NAMS annual long term assets is $1.21 million

Current assets

$863.41M
NAMS annual total current assets is $863.41 million

Cash and cash equivalents

$771.74M
NAMS annual cash & cash equivalents is $771.74 million

Accounts receivable

-
NAMS annual accounts receivable value is unknown

Inventory

-
NAMS annual inventory value is unknown

Liabilities

Total liabilities

$107.12M
NAMS annual total liabilities is $107.12 million

Long term liabilities

$202.00K
NAMS annual total long term liabilities is $202.00 thousand

Current liabilities

$106.92M
NAMS annual total current liabilities is $106.92 million

Accounts payable

$4.74M
NAMS annual accounts payable is $4.74 million

Debt

Total debt

$448.00K
NAMS annual total debt is $448.00 thousand

Total debt 1-year change

+646.67%
NAMS annual total debt is up +646.67% year-on-year

Long term debt

$202.00K
NAMS annual long term debt is $202.00 thousand

Short term debt

$246.00K
NAMS annual short term debt is $246.00 thousand

Equity & Capital

Shareholders equity

$757.50M
NAMS annual stockholders equity is $757.50 million

Book value

$757.50M
NAMS annual book value is $757.50 million

Retained earnings

-$558.57M
NAMS annual retained earnings is -$558.57 million

Working capital

$756.50M
NAMS annual working capital is $756.50 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$158.56M
NAMS annual cash flow from operations is -$158.56 million

Cash from operations 1-year change

-12.28%
NAMS annual cash flow from operations is down -12.28% year-on-year

Cash from investing

-$62.85M
NAMS annual cash flow from investing activities is -$62.85 million

Cash from investing 1-year change

-261766.67%
NAMS annual cash flow from investing activities is down -261766.67% year-on-year

Cash from financing

$659.51M
NAMS annual cash flow from financing activities is $659.51 million

Cash from financing 1-year change

+7300.21%
NAMS annual cash flow from financing activities is up +7300.21% year-on-year

CAPEX

CAPEX

$672.00K
NAMS annual capital expenditures is $672.00 thousand

CAPEX 1-year change

+2700%
NAMS annual capital expenditures is up +2700% year-on-year

Free Cash Flow

Free cash flow

-$159.24M
NAMS annual free cash flow is -$159.24 million

Free cash flow 1-year change

-12.74%
NAMS annual free cash flow is down -12.74% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
NAMS annual gross profit margin value is unknown

Operating margin

-386.91%
NAMS annual operating profit margin is -386.91%

Net margin

-530.25%
NAMS annual net profit margin is -530.25%

ROA & ROE

ROA

-39.88%
NAMS annual return on assets is -39.88%

ROE

-46.20%
NAMS annual return on equity is -46.20%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
NAMS price to earnings ratio value is unknown

PE ratio Sector rank

-
NAMS price to earnings ratio is unknown

PB Ratio

PB ratio

2.37
NAMS price to book ratio is 2.37

PB ratio Sector rank

67.3%
NAMS price to book ratio is higher than 67.3% of companies in Healthcare sector

PS Ratio

PS ratio

39.38
NAMS price to sales ratio is 39.38

PS ratio Sector rank

90.9%
NAMS price to sales ratio is higher than 90.9% of companies in Healthcare sector

Enterprise value

Enterprise value

$1.02B
NAMS enterprise value is $1.02 billion

Enterprise value Sector rank

75.56%
NAMS enterprise value is higher than 75.56% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-4.24
NAMS EV/EBITDA is -4.24

EV/EBITDA Sector rank

20.52%
NAMS EV/EBITDA is higher than 20.52% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

8.08
NAMS annual current ratio is 8.08

Quick ratio

-
NAMS annual quick ratio value is unknown

Leverage

Debt to equity

0.00
NAMS annual debt to equity ratio is 0.00

Interest coverage ratio

-
NAMS annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
NAMS piotroski f-score value is unknown

Altman Z-Score

9.33
NAMS altman z-score is 9.33

Analyst ratings

Recent major analysts updates

Apr 8, 25 Needham
Buy
Feb 27, 25 Scotiabank
Sector Outperform
Feb 27, 25 Needham
Buy
Jan 28, 25 RBC Capital
Outperform
Jan 24, 25 RBC Capital
Outperform
Jan 14, 25 HC Wainwright & Co.
Buy
Dec 30, 24 HC Wainwright & Co.
Buy
Dec 11, 24 Scotiabank
Sector Outperform
Dec 5, 24 Needham
Buy
Nov 21, 24 Needham
Buy

Institutional Ownership

Similar stocks

PINC logo
Premier (PINC)
Ardent Health Partners LLC (ARDT)
ENOV logo
Enovis (ENOV)
NVCR logo
NovoCure Limited (NVCR)
WRBY logo
Warby Parker (WRBY)
SUPN logo
Supernus Pharmaceuticals (SUPN)
GDRX logo
GoodRx Holdings (GDRX)
QDEL logo
QuidelOrtho (QDEL)
DNLI logo
Denali Therapeutics (DNLI)
  • What is the ticker symbol for NewAmsterdam Pharma Company NV?
  • Does NewAmsterdam Pharma Company NV pay dividends?
  • What sector is NewAmsterdam Pharma Company NV in?
  • What industry is NewAmsterdam Pharma Company NV in?
  • What country is NewAmsterdam Pharma Company NV based in?
  • When did NewAmsterdam Pharma Company NV go public?
  • Is NewAmsterdam Pharma Company NV in the S&P 500?
  • Is NewAmsterdam Pharma Company NV in the NASDAQ 100?
  • Is NewAmsterdam Pharma Company NV in the Dow Jones?
  • When was NewAmsterdam Pharma Company NV's last earnings report?
  • When does NewAmsterdam Pharma Company NV report earnings?
  • Should I buy NewAmsterdam Pharma Company NV stock now?

What is the ticker symbol for NewAmsterdam Pharma Company NV?

The ticker symbol for NewAmsterdam Pharma Company NV is NASDAQ:NAMS

Does NewAmsterdam Pharma Company NV pay dividends?

No, NewAmsterdam Pharma Company NV does not pay dividends

What sector is NewAmsterdam Pharma Company NV in?

NewAmsterdam Pharma Company NV is in the Healthcare sector

What industry is NewAmsterdam Pharma Company NV in?

NewAmsterdam Pharma Company NV is in the Biotechnology industry

What country is NewAmsterdam Pharma Company NV based in?

NewAmsterdam Pharma Company NV is headquartered in Netherlands

When did NewAmsterdam Pharma Company NV go public?

NewAmsterdam Pharma Company NV's initial public offering (IPO) was on February 9, 2021

Is NewAmsterdam Pharma Company NV in the S&P 500?

No, NewAmsterdam Pharma Company NV is not included in the S&P 500 index

Is NewAmsterdam Pharma Company NV in the NASDAQ 100?

No, NewAmsterdam Pharma Company NV is not included in the NASDAQ 100 index

Is NewAmsterdam Pharma Company NV in the Dow Jones?

No, NewAmsterdam Pharma Company NV is not included in the Dow Jones index

When was NewAmsterdam Pharma Company NV's last earnings report?

NewAmsterdam Pharma Company NV's most recent earnings report was on Feb 26, 2025

When does NewAmsterdam Pharma Company NV report earnings?

The next expected earnings date for NewAmsterdam Pharma Company NV is May 9, 2025

Should I buy NewAmsterdam Pharma Company NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page